A Multicenter Study of Crisaborole Use in Pediatric Patients with Atopic Dermatitis in Real-World Setting in Thailand
- Conditions
- Atopic dermatitisAtopic dermatitis, Children
- Registration Number
- TCTR20230421004
- Lead Sponsor
- Pfizer (Thailand) Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
1. Atopic patients, older than 3 months-18 years old, with a baseline Investigator Static Global Assessment (ISGA) score of mild and moderate severity
2. Agree to participate in the study
3. Wash out period: topical treatment >2 weeks, systemic treatment included biologic agents > 4 weeks
Exclusion Criteria
Atopic patients with skin infection or immunocompromised patient
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of AD 4 week ISGA score
- Secondary Outcome Measures
Name Time Method pruritus 4 week pruritus scale